수의 종양학 시장 : 규모, 점유율, 성장, 세계 산업 분석, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of veterinary oncology Market

The global veterinary oncology market was valued at USD 2.90 billion in 2025 and is projected to grow from USD 3.15 billion in 2026 to USD 7.11 billion by 2034, exhibiting a CAGR of 10.70% during the forecast period. North America dominated the global market with a 47.58% market share in 2025, driven by high pet ownership, advanced veterinary healthcare infrastructure, and increasing adoption of specialized cancer diagnosis and treatment services.

Veterinary oncology focuses on the diagnosis, treatment, and management of cancer in companion animals, particularly dogs and cats. The market includes advanced diagnostic technologies, laboratory services, imaging systems, chemotherapy drugs, targeted therapies, cancer vaccines, and supportive oncology treatments. Rising pet humanization, increasing spending on animal healthcare, and growing awareness of early cancer detection are significantly contributing to market expansion. Continuous advancements in molecular diagnostics, liquid biopsy, AI-assisted imaging, and personalized treatment approaches are further strengthening the industry's growth prospects.

Veterinary Oncology Market Trends

A major trend shaping the veterinary oncology market is the rapid advancement of cancer diagnostics and personalized treatment options. Veterinary clinics and specialty hospitals are increasingly adopting cytology, histopathology, immunophenotyping, molecular diagnostics, liquid biopsy, and AI-powered imaging solutions for earlier and more accurate cancer detection. These technologies enable veterinarians to diagnose tumors at earlier stages and recommend targeted treatment plans. At the same time, the availability of targeted cancer drugs, lymphoma-specific therapies, cancer vaccines, and supportive care medications is improving survival rates and enhancing the quality of life for companion animals.

Market Drivers

The increasing awareness of pet health and preventive veterinary care is one of the primary drivers of the veterinary oncology market growth. Pet owners are becoming more willing to invest in advanced diagnostic tests and cancer treatments as companion animals are increasingly regarded as family members. The growing population of aging pets, which are more susceptible to cancer, has significantly increased the demand for oncology diagnostics and therapeutics. In addition, new product launches, expanding veterinary specialty hospitals, and improved access to oncology services are supporting market development worldwide.

Market Restraints

Despite strong growth potential, the market faces several restraints. Advanced cancer treatments, including chemotherapy, radiation therapy, targeted drugs, and specialized diagnostics, remain expensive for many pet owners. Limited availability of veterinary oncology specialists and advanced treatment facilities in developing countries further restricts market expansion. In addition, low penetration of pet insurance in many regions reduces affordability, causing many owners to opt for basic treatment or palliative care instead of comprehensive cancer management.

Market Opportunities

Technological innovation in veterinary diagnostics offers significant growth opportunities for the market. New diagnostic tools such as blood-based cancer screening, liquid biopsy, digital pathology, AI-assisted imaging, and molecular testing enable earlier cancer detection and more effective treatment planning. These technologies increase the number of animals entering oncology care while creating recurring demand for laboratory testing, consumables, and monitoring services. Expanding companion animal healthcare in emerging economies is also expected to generate substantial long-term market opportunities.

Market Segmentation

Based on offering, the market is divided into diagnostics and therapeutics. The diagnostics segment dominated the market in 2025 due to the growing importance of early cancer detection, staging, monitoring, and treatment planning. The therapeutics segment is expected to witness faster growth with increasing adoption of chemotherapy, targeted therapies, and immunotherapy.

By cancer type, lymphoma accounted for the largest market share owing to its high diagnosis rate among companion animals, especially dogs. Availability of lymphoma-specific drugs and advanced diagnostic technologies continues to support this segment. Mast cell tumors are also expected to register strong growth during the forecast period.

Based on animal type, the canine segment dominated the global market due to higher cancer incidence, wider availability of dog-specific oncology treatments, and greater owner willingness to pursue advanced therapies. The feline segment is also expected to grow steadily as awareness and treatment options continue to improve.

Regional Outlook

North America remained the leading regional market with a value of USD 1.38 billion in 2025. The region benefits from strong veterinary infrastructure, high pet healthcare expenditure, widespread availability of oncology specialists, and continuous technological innovation. The U.S. continues to dominate regional revenues through advanced companion animal healthcare services and strong adoption of oncology diagnostics.

Europe represents the second-largest regional market, supported by high companion animal ownership, established veterinary healthcare systems, and increasing availability of specialty oncology clinics. Countries including Germany and the U.K. continue to invest in advanced veterinary diagnostic laboratories and cancer treatment services.

Asia Pacific is expected to witness the fastest market growth due to rising pet ownership, urbanization, increasing disposable income, and growing awareness regarding companion animal healthcare across China, Japan, India, South Korea, and Australia. Expansion of veterinary hospitals and diagnostic laboratories is further strengthening regional demand.

Latin America and the Middle East & Africa are gradually expanding as improving veterinary infrastructure, premium pet care services, and increasing awareness of animal health encourage adoption of advanced cancer diagnostics and treatments.

Competitive Landscape

The veterinary oncology market is moderately fragmented, with leading companies focusing on expanding diagnostic capabilities, oncology drug portfolios, laboratory services, and precision medicine technologies. Major industry participants include IDEXX Laboratories, Inc., Zoetis Services LLC., Antech Diagnostics, Inc., Volition, Elanco, Dechra Limited, Boehringer Ingelheim International GmbH, Oncotect, Virbac, and Novavive Inc. These companies continue investing in cancer screening technologies, AI-assisted diagnostics, targeted therapeutics, and companion animal oncology research to strengthen their competitive position.

Recent developments highlight the industry's rapid innovation. In 2026, Avammune advanced clinical trials for its Enzistat cancer drug in dogs with terminal tumors. During 2025, Yale's canine cancer vaccine program continued multi-center clinical trials, while Cornell University researchers introduced AI-based pathology tools and non-invasive tumor monitoring technologies. These innovations are expected to significantly improve cancer diagnosis and treatment outcomes for companion animals.

Conclusion

The global veterinary oncology market is witnessing strong growth due to increasing pet ownership, rising awareness of animal cancer care, expanding diagnostic capabilities, and continuous innovation in veterinary therapeutics. Valued at USD 2.90 billion in 2025, the market is projected to reach USD 3.15 billion in 2026 and USD 7.11 billion by 2034, supported by advancements in precision diagnostics, personalized treatment approaches, AI-enabled technologies, and growing investment in companion animal healthcare worldwide.

Segmentation By Offering, Cancer Type, Animal Type, and Region

By Offering * Diagnostics

• By Product
• Instruments
• Reagents & Consumables
  • By Technique
• Cytology
• Histopathology / Anatomic Pathology
• Hematology
• Clinical Biochemistry
• Immunodiagnostics
• Molecular Diagnostics
• Others
• Therapeutics
  • By Drug Class
• Cytotoxic Chemotherapy Drugs
• Targeted Anticancer Drugs
• Cancer Vaccines
• Hormonal Drugs
• Corticosteroids
• Others
  • By Therapy Type
• Targeted Therapy
• Chemotherapy
• Immunotherapy
• Others

By Cancer Type * Lymphoma

• Mast Cell Tumor
• Melanoma
• Osteosarcoma
• Mammary Tumors
• Soft Tissue Sarcoma
• Hemangiosarcoma
• Squamous Cell Carcinoma
• Others

By Animal Type * Canine

• Feline
• Equine
• Others

By Region * North America (By Offering, Cancer Type, Animal Type, and Country)

• U.S.
• Canada
• Europe (By Offering, Cancer Type, Animal Type, and Country/Sub-region)
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Offering, Cancer Type, Animal Type, and Country/Sub-region)
  • China
  • Japan
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Offering, Cancer Type, Animal Type, and Country/Sub-region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Offering, Cancer Type, Animal Type, and Country/Sub-region)
  • GCC
  • South Africa
  • Rest of the Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Challenges
• 3.5. Market Trends

4. Key Insights

• 4.1. Prevalence of Key Diseases, By Key Countries/Region, 2025
• 4.2. Pipeline Analysis, By Key Players
• 4.3. Overview: Advancements in Veterinary Diagnostics
• 4.4. Key Industry Developments (Mergers, Acquisitions, Partnerships, and Others)
• 4.5. New Product Launches, By Key Players

5. Global Veterinary Oncology Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Offering
  • 5.1.1. Diagnostics
    • 5.1.1.1. By Product
      • 5.1.1.1.1. Instruments
      • 5.1.1.1.2. Reagents & Consumables
    • 5.1.1.2. By Technique
      • 5.1.1.2.1. Cytology
      • 5.1.1.2.2. Histopathology / Anatomic Pathology
      • 5.1.1.2.3. Hematology
      • 5.1.1.2.4. Clinical Biochemistry
      • 5.1.1.2.5. Immunodiagnostics
      • 5.1.1.2.6. Molecular Diagnostics
      • 5.1.1.2.7. Others
  • 5.1.2. Therapeutics
    • 5.1.2.1. By Drug Class
      • 5.1.2.1.1. Cytotoxic Chemotherapy Drugs
      • 5.1.2.1.2. Targeted Anticancer Drugs
      • 5.1.2.1.3. Cancer Vaccines
      • 5.1.2.1.4. Hormonal Drugs
      • 5.1.2.1.5. Corticosteroids
      • 5.1.2.1.6. Others
    • 5.1.2.2. By Therapy Type
      • 5.1.2.2.1. Targeted Therapy
      • 5.1.2.2.2. Chemotherapy
      • 5.1.2.2.3. Immunotherapy
      • 5.1.2.2.4. Others
• 5.2. Market Analysis, Insights and Forecast - By Cancer Type
  • 5.2.1. Lymphoma
  • 5.2.2. Mast Cell Tumor
  • 5.2.3. Melanoma
  • 5.2.4. Osteosarcoma
  • 5.2.5. Mammary Tumors
  • 5.2.6. Soft Tissue Sarcoma
  • 5.2.7. Hemangiosarcoma
  • 5.2.8. Squamous Cell Carcinoma
  • 5.2.9. Others
• 5.3. Market Analysis, Insights and Forecast - By Animal Type
  • 5.3.1. Canine
  • 5.3.2. Feline
  • 5.3.3. Equine
  • 5.3.4. Others
• 5.4. Market Analysis, Insights and Forecast - Region
  • 5.4.1. North America
  • 5.4.2. Europe
  • 5.4.3. Asia Pacific
  • 5.4.4. Latin America
  • 5.4.5. Middle East & Africa

6. North America Veterinary Oncology Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Offering
  • 6.1.1. Diagnostics
    • 6.1.1.1. By Product
      • 6.1.1.1.1. Instruments
      • 6.1.1.1.2. Reagents & Consumables
    • 6.1.1.2. By Technique
      • 6.1.1.2.1. Cytology
      • 6.1.1.2.2. Histopathology / Anatomic Pathology
      • 6.1.1.2.3. Hematology
      • 6.1.1.2.4. Clinical Biochemistry
      • 6.1.1.2.5. Immunodiagnostics
      • 6.1.1.2.6. Molecular Diagnostics
      • 6.1.1.2.7. Others
  • 6.1.2. Therapeutics
    • 6.1.2.1. By Drug Class
      • 6.1.2.1.1. Cytotoxic Chemotherapy Drugs
      • 6.1.2.1.2. Targeted Anticancer Drugs
      • 6.1.2.1.3. Cancer Vaccines
      • 6.1.2.1.4. Hormonal Drugs
      • 6.1.2.1.5. Corticosteroids
      • 6.1.2.1.6. Others
    • 6.1.2.2. By Therapy Type
      • 6.1.2.2.1. Targeted Therapy
      • 6.1.2.2.2. Chemotherapy
      • 6.1.2.2.3. Immunotherapy
      • 6.1.2.2.4. Others
• 6.2. Market Analysis, Insights and Forecast - By Cancer Type
  • 6.2.1. Lymphoma
  • 6.2.2. Mast Cell Tumor
  • 6.2.3. Melanoma
  • 6.2.4. Osteosarcoma
  • 6.2.5. Mammary Tumors
  • 6.2.6. Soft Tissue Sarcoma
  • 6.2.7. Hemangiosarcoma
  • 6.2.8. Squamous Cell Carcinoma
  • 6.2.9. Others
• 6.3. Market Analysis, Insights and Forecast - By Animal Type
  • 6.3.1. Canine
  • 6.3.2. Feline
  • 6.3.3. Equine
  • 6.3.4. Others
• 6.4. Market Analysis, Insights and Forecast - By Country
  • 6.4.1. U.S.
  • 6.4.2. Canada

7. Europe Veterinary Oncology Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Offering
  • 7.1.1. Diagnostics
    • 7.1.1.1. By Product
      • 7.1.1.1.1. Instruments
      • 7.1.1.1.2. Reagents & Consumables
    • 7.1.1.2. By Technique
      • 7.1.1.2.1. Cytology
      • 7.1.1.2.2. Histopathology / Anatomic Pathology
      • 7.1.1.2.3. Hematology
      • 7.1.1.2.4. Clinical Biochemistry
      • 7.1.1.2.5. Immunodiagnostics
      • 7.1.1.2.6. Molecular Diagnostics
      • 7.1.1.2.7. Others
  • 7.1.2. Therapeutics
    • 7.1.2.1. By Drug Class
      • 7.1.2.1.1. Cytotoxic Chemotherapy Drugs
      • 7.1.2.1.2. Targeted Anticancer Drugs
      • 7.1.2.1.3. Cancer Vaccines
      • 7.1.2.1.4. Hormonal Drugs
      • 7.1.2.1.5. Corticosteroids
      • 7.1.2.1.6. Others
    • 7.1.2.2. By Therapy Type
      • 7.1.2.2.1. Targeted Therapy
      • 7.1.2.2.2. Chemotherapy
      • 7.1.2.2.3. Immunotherapy
      • 7.1.2.2.4. Others
• 7.2. Market Analysis, Insights and Forecast - By Cancer Type
  • 7.2.1. Lymphoma
  • 7.2.2. Mast Cell Tumor
  • 7.2.3. Melanoma
  • 7.2.4. Osteosarcoma
  • 7.2.5. Mammary Tumors
  • 7.2.6. Soft Tissue Sarcoma
  • 7.2.7. Hemangiosarcoma
  • 7.2.8. Squamous Cell Carcinoma
  • 7.2.9. Others
• 7.3. Market Analysis, Insights and Forecast - By Animal Type
  • 7.3.1. Canine
  • 7.3.2. Feline
  • 7.3.3. Equine
  • 7.3.4. Others
• 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 7.4.1. U.K.
  • 7.4.2. Germany
  • 7.4.3. France
  • 7.4.4. Italy
  • 7.4.5. Spain
  • 7.4.6. Scandinavia
  • 7.4.7. Rest of Europe

8. Asia Pacific Veterinary Oncology Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Offering
  • 8.1.1. Diagnostics
    • 8.1.1.1. By Product
      • 8.1.1.1.1. Instruments
      • 8.1.1.1.2. Reagents & Consumables
    • 8.1.1.2. By Technique
      • 8.1.1.2.1. Cytology
      • 8.1.1.2.2. Histopathology / Anatomic Pathology
      • 8.1.1.2.3. Hematology
      • 8.1.1.2.4. Clinical Biochemistry
      • 8.1.1.2.5. Immunodiagnostics
      • 8.1.1.2.6. Molecular Diagnostics
      • 8.1.1.2.7. Others
  • 8.1.2. Therapeutics
    • 8.1.2.1. By Drug Class
      • 8.1.2.1.1. Cytotoxic Chemotherapy Drugs
      • 8.1.2.1.2. Targeted Anticancer Drugs
      • 8.1.2.1.3. Cancer Vaccines
      • 8.1.2.1.4. Hormonal Drugs
      • 8.1.2.1.5. Corticosteroids
      • 8.1.2.1.6. Others
    • 8.1.2.2. By Therapy Type
      • 8.1.2.2.1. Targeted Therapy
      • 8.1.2.2.2. Chemotherapy
      • 8.1.2.2.3. Immunotherapy
      • 8.1.2.2.4. Others
• 8.2. Market Analysis, Insights and Forecast - By Cancer Type
  • 8.2.1. Lymphoma
  • 8.2.2. Mast Cell Tumor
  • 8.2.3. Melanoma
  • 8.2.4. Osteosarcoma
  • 8.2.5. Mammary Tumors
  • 8.2.6. Soft Tissue Sarcoma
  • 8.2.7. Hemangiosarcoma
  • 8.2.8. Squamous Cell Carcinoma
  • 8.2.9. Others
• 8.3. Market Analysis, Insights and Forecast - By Animal Type
  • 8.3.1. Canine
  • 8.3.2. Feline
  • 8.3.3. Equine
  • 8.3.4. Others
• 8.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 8.4.1. China
  • 8.4.2. Japan
  • 8.4.3. India
  • 8.4.4. Australia
  • 8.4.5. Southeast Asia
  • 8.4.6. Rest of Asia Pacific

9. Latin America Veterinary Oncology Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Offering
  • 9.1.1. Diagnostics
    • 9.1.1.1. By Product
      • 9.1.1.1.1. Instruments
      • 9.1.1.1.2. Reagents & Consumables
    • 9.1.1.2. By Technique
      • 9.1.1.2.1. Cytology
      • 9.1.1.2.2. Histopathology / Anatomic Pathology
      • 9.1.1.2.3. Hematology
      • 9.1.1.2.4. Clinical Biochemistry
      • 9.1.1.2.5. Immunodiagnostics
      • 9.1.1.2.6. Molecular Diagnostics
      • 9.1.1.2.7. Others
  • 9.1.2. Therapeutics
    • 9.1.2.1. By Drug Class
      • 9.1.2.1.1. Cytotoxic Chemotherapy Drugs
      • 9.1.2.1.2. Targeted Anticancer Drugs
      • 9.1.2.1.3. Cancer Vaccines
      • 9.1.2.1.4. Hormonal Drugs
      • 9.1.2.1.5. Corticosteroids
      • 9.1.2.1.6. Others
    • 9.1.2.2. By Therapy Type
      • 9.1.2.2.1. Targeted Therapy
      • 9.1.2.2.2. Chemotherapy
      • 9.1.2.2.3. Immunotherapy
      • 9.1.2.2.4. Others
• 9.2. Market Analysis, Insights and Forecast - By Cancer Type
  • 9.2.1. Lymphoma
  • 9.2.2. Mast Cell Tumor
  • 9.2.3. Melanoma
  • 9.2.4. Osteosarcoma
  • 9.2.5. Mammary Tumors
  • 9.2.6. Soft Tissue Sarcoma
  • 9.2.7. Hemangiosarcoma
  • 9.2.8. Squamous Cell Carcinoma
  • 9.2.9. Others
• 9.3. Market Analysis, Insights and Forecast - By Animal Type
  • 9.3.1. Canine
  • 9.3.2. Feline
  • 9.3.3. Equine
  • 9.3.4. Others
• 9.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 9.4.1. Brazil
  • 9.4.2. Mexico
  • 9.4.3. Rest of Latin America

10. Middle East & Africa Veterinary Oncology Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Offering
  • 10.1.1. Diagnostics
    • 10.1.1.1. By Product
      • 10.1.1.1.1. Instruments
      • 10.1.1.1.2. Reagents & Consumables
    • 10.1.1.2. By Technique
      • 10.1.1.2.1. Cytology
      • 10.1.1.2.2. Histopathology / Anatomic Pathology
      • 10.1.1.2.3. Hematology
      • 10.1.1.2.4. Clinical Biochemistry
      • 10.1.1.2.5. Immunodiagnostics
      • 10.1.1.2.6. Molecular Diagnostics
      • 10.1.1.2.7. Others
  • 10.1.2. Therapeutics
    • 10.1.2.1. By Drug Class
      • 10.1.2.1.1. Cytotoxic Chemotherapy Drugs
      • 10.1.2.1.2. Targeted Anticancer Drugs
      • 10.1.2.1.3. Cancer Vaccines
      • 10.1.2.1.4. Hormonal Drugs
      • 10.1.2.1.5. Corticosteroids
      • 10.1.2.1.6. Others
    • 10.1.2.2. By Therapy Type
      • 10.1.2.2.1. Targeted Therapy
      • 10.1.2.2.2. Chemotherapy
      • 10.1.2.2.3. Immunotherapy
      • 10.1.2.2.4. Others
• 10.2. Market Analysis, Insights and Forecast - By Cancer Type
  • 10.2.1. Lymphoma
  • 10.2.2. Mast Cell Tumor
  • 10.2.3. Melanoma
  • 10.2.4. Osteosarcoma
  • 10.2.5. Mammary Tumors
  • 10.2.6. Soft Tissue Sarcoma
  • 10.2.7. Hemangiosarcoma
  • 10.2.8. Squamous Cell Carcinoma
  • 10.2.9. Others
• 10.3. Market Analysis, Insights and Forecast - By Animal Type
  • 10.3.1. Canine
  • 10.3.2. Feline
  • 10.3.3. Equine
  • 10.3.4. Others
• 10.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 10.4.1. GCC
  • 10.4.2. South Africa
  • 10.4.3. Rest of the Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. IDEXX Laboratories, Inc.
  • 11.2.2. Zoetis Services LLC.
  • 11.2.3. Antech Diagnostics, Inc
  • 11.2.4. Volition
  • 11.2.5. Elanco
  • 11.2.6. Dechra Limited
  • 11.2.7. Boehringer Ingelheim International GmbH
  • 11.2.8. Oncotect
  • 11.2.9. Virbac
  • 11.2.10. Novavive Inc.